Literature DB >> 7609780

Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits.

B Szabo1, R Urban, N Limberger, K Starke.   

Abstract

Agmatine has been identified as a "clonidine-displacing substance" in extracts from bovine brain. We studied its effect on cardiovascular regulation and the role played in this effect by alpha 2-adrenoceptors. In conscious rabbits, agmatine 10 micrograms kg-1 injected intracisternally (i.c.) caused no change, whereas agmatine 30, 100 and 300 micrograms kg-1 i.c. increased renal sympathetic nerve firing, the plasma concentration of noradrenaline and adrenaline and arterial blood pressure. Heart rate tended to be decreased. Yohimbine 1.5 micrograms kg-1 i.c. caused no change, whereas yohimbine 5, 15 and 50 micrograms kg-1 increased renal sympathetic nerve activity, the plasma concentration of noradrenaline and adrenaline, blood pressure and heart rate. In rabbit brain cortex slices preincubated with [3H]-noradrenaline, agmatine 1 to 100 microM did not modify the electrically evoked overflow of tritium (either 4 pulses at 100 Hz or 36 pulses at 3 Hz). The evoked overflow was reduced by 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline (UK 14304) 0.03 to 30 nM (4 pulses at 100 Hz), and this inhibition was not affected by agmatine 10 and 100 microM. Agmatine did not change the basal efflux of tritium. The results show that agmatine, like yohimbine, causes central sympathoexcitation when given i.c., but agmatine differs from yohimbine in that it does not increase heart rate. Agmatine acts neither as an agonist nor as an antagonist at the alpha 2-autoreceptors in rabbit brain cortex. alpha 2-Adrenoceptors, therefore, are probably not involved in its cardiovascular effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609780     DOI: 10.1007/BF00233246

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

1.  Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study.

Authors:  A P Nicholas; V Pieribone; T Hökfelt
Journal:  J Comp Neurol       Date:  1993-02-22       Impact factor: 3.215

2.  Transmitter sensitivity of neurons assayed by autoradiography.

Authors:  D Yoshikami
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728

3.  Peripheral presynaptic and central effects of clonidine, yohimbine and rauwolscine on the sympathetic nervous system in rabbits.

Authors:  B Szabo; L Hedler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

4.  Desipramine inhibits sympathetic nerve activity in the rabbit.

Authors:  B Sazbo; A Schultheiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

5.  Are the prejunctional alpha 2-adrenoceptors of the rat vas deferens and submandibular gland of the alpha 2A- or alpha 2D-subtype?

Authors:  K Smith; J R Docherty
Journal:  Eur J Pharmacol       Date:  1992-08-25       Impact factor: 4.432

6.  Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit.

Authors:  A U Trendelenburg; N Limberger; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

7.  Isolation and partial purification of a clonidine-displacing endogenous brain substance.

Authors:  D Atlas; Y Burstein
Journal:  Eur J Biochem       Date:  1984-10-15

8.  Contribution of noradrenergic and serotonergic neurons to the circulatory effects of centrally acting clonidine and alpha-methyldopa in rabbits.

Authors:  G A Head; P I Korner; S L Lewis; E Badoer
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

9.  Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum.

Authors:  M P Meeley; M L Hensley; P Ernsberger; D Felsen; D J Reis
Journal:  Biochem Pharmacol       Date:  1992-08-18       Impact factor: 5.858

10.  Central cardiovascular effects of a noncatecholamine endogenous ligand for clonidine receptors.

Authors:  P Bousquet; J Feldman; D Atlas
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  7 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 2.  Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence.

Authors:  Soundar Regunathan
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

3.  Dual interaction of agmatine with the rat alpha(2D)-adrenoceptor: competitive antagonism and allosteric activation.

Authors:  G J Molderings; S Menzel; M Kathmann; E Schlicker; M Göthert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

5.  Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.

Authors:  Walter Raasch; Ulrich Schäfer; Fatimunnisa Qadri; Peter Dominiak
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Remigiusz Czernecki; Katarzyna Wojtal; Kinga K Borowicz; Stanislaw J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-04-01       Impact factor: 3.575

7.  Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system.

Authors:  Feyza Aricioglu; Andrea Means; Soundar Regunathan
Journal:  Eur J Pharmacol       Date:  2004-11-19       Impact factor: 4.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.